Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30131242 | 0.82 | SLC6A2 (0.53) | SLC6A4TAAR1SLC18A2SIGMAR1ACACB | |
| SCHEMBL13416485 | 0.81 | SIGMAR1 (0.63) | SLC6A4TAAR1SLC18A2SIGMAR1KMT2A | |
| SCHEMBL13416383 | 0.81 | SIGMAR1 (0.63) | SLC6A4TAAR1SLC18A2SIGMAR1KMT2A | |
| SCHEMBL765297 | 0.78 | TAAR1 (0.65) | SLC6A4TAAR1SLC18A2SIGMAR1ACACB | |
| SCHEMBL8676494 | 0.73 | TRPA1 (0.47) | TAAR1ACACBKMT2ATSHRMAPK1 | |
| SCHEMBL1178159 | 0.72 | PTGS1 (0.48) | TAAR1TSHRMAPK1ATMTDP1 | |
| SCHEMBL178497 | 0.70 | L3MBTL1 (0.48) | TAAR1PLK1TSHRMAPK1ATM | |
| SCHEMBL178495 | 0.70 | L3MBTL1 (0.48) | TAAR1PLK1TSHRMAPK1ATM | |
| SCHEMBL8285049 | 0.70 | L3MBTL1 (0.48) | TAAR1PLK1TSHRMAPK1ATM | |
| SCHEMBL19937538 | 0.69 | L3MBTL1 (0.40) | SLC6A4TAAR1PLK1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | SLC6A4 4734/4885TAAR1 4852/4885SLC18A2 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.